At a glance
Roche continues driving one of this industry’s best product pipelines. In 2019, we invested about one fifth of the company’s sales to develop new tests and medicines for patients in need of new options. A leader in oncology, we are now also entering new disease areas with very low incidence rates. These include multiple sclerosis, haemophilia and neuroscience disesases.